Latest Market Integration News

Capricorn Metals Ltd has had its CMMO securities class suspended from ASX trading pending regulatory compliance, raising questions about the company’s next steps.

Stealth Group Holdings has acquired Hardware & Building Traders for $22 million, significantly expanding its footprint and upgrading its FY28 sales target to over $500 million. The deal positions Stealth as a formidable independent competitor in Australia’s hardware and industrial distribution market.

DroneShield Limited has clarified the recent sharp decline in its share price, attributing the market movement to disclosed director share disposals rather than any undisclosed material information.

Resolution Minerals has clarified its compliance with ASX disclosure rules following a $2 million placement to Tribeca Investment Partners, confirming the transaction's material impact on its share price.

Sagalio Energy’s shares surged sharply on November 12, prompting ASX to demand clarity on undisclosed information and compliance with disclosure rules.

Mt Malcolm Mines NL has suspended trading of its M2MOA securities pending regulatory compliance, signaling a cautious pause for investors.

Vectus Biosystems has responded to an ASX price query following a dramatic spike in its share price and trading volume, denying any undisclosed information and confirming compliance with ASX rules.

Stealth Group Holdings has acquired Hardware & Building Traders for $22 million, creating Australia’s largest integrated hardware and industrial distribution platform and upgrading its FY28 financial outlook.

Invex Therapeutics Ltd has been suspended from trading on the ASX due to a failure to maintain the minimum number of directors required by law. The suspension will remain until the company rectifies its governance structure and complies with listing rules.

Finexia Financial Group Limited (ASX – FNX) has had its trading suspension lifted immediately following its public response to recent media speculation. The reinstatement marks a pivotal moment for the financial group’s market activity.

James Hardie Industries faces intense scrutiny from the ASX after its share price dropped sharply and trading volumes spiked, prompting urgent questions about undisclosed information.

Chimeric Therapeutics has responded to ASX inquiries regarding the disclosure timing and materiality of new clinical data from its ADVENT-AML trial, emphasizing compliance with continuous disclosure rules and the careful verification of promising patient responses.